Serum Levels of Epidermal Growth Factor, Transforming Growth Factor, and c-erbB2 in Ovarian Cancer

ObjectiveThis study aimed to investigate serum levels of epidermal growth factor (EGF), transforming growth factor α (TGF-α), and c-erbB2 in patients with ovarian cancer.Materials and MethodsIn this retrospective cohort study, the study and control groups were composed of 43 women with a prediagnosis of ovarian cancer and 43 healthy women, respectively. Blood samples from all women were obtained and studied by enzyme-linked immunosorbent assay kits for EGF, TGF-α, and c-erbB2. After surgery of the study group, ovarian cancer was confirmed and compared with control group. Stage, grade, and histological types were defined after histopathologic examination, and subgroups were constructed and compared.ResultsSerum EGF, TGF-α, and c-erbB2 levels were significantly increased in study group compared with those in the control group (P < 0.001). There were no differences in serum levels of EGF, TGF-α, and c-erbB2 among all stages, grades, and histological types of ovarian cancer. If 47.90 pg/mL was selected as the cutoff value, EGF has an 80% sensitivity and a 65% specificity for detecting ovarian cancer. The cutoff value of 41,095.00 pg/mL for TGF-α has a 90% sensitivity and a 72% specificity for detecting ovarian cancer. The c-erbB2 level of 4.63 pg/mL as the cutoff value has an 83% sensitivity and a 76% specificity for predicting ovarian cancer.ConclusionsSerum levels of EGF, TGF-α, and c-erbB2 may be used for diagnosing ovarian cancer.

Download Full-text

Elevated Epidermal Growth Factor (EGF) as Candidate Biomarker of Mood Disorders—Longitudinal Study in Adolescent and Young Adult Patients

Journal of Clinical Medicine ◽

10.3390/jcm10184064 ◽

2021 ◽

Vol 10 (18) ◽

pp. 4064

Author(s):

Maria Skibinska ◽

Pawel Kapelski ◽

Monika Dmitrzak-Weglarz ◽

Natalia Lepczynska ◽

Joanna Pawlak ◽

...

Keyword(s):

Bipolar Disorder ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Mood Disorders ◽

Young Patients ◽

Serum Levels ◽

Adolescent And Young Adult ◽

Control Group ◽

Replication Studies ◽

Epidermal Growth

Bipolar disorder (BD) is a chronic mental disorder that affects more than 1% of the population worldwide. Over 65% of patients experience early onset of the disease. Most cases of juvenile bipolar disorder begin with a depressed mood episode, and up to 50% of youth initially diagnosed with major depression go onto developing a BD. Our study aimed to find biomarkers of diagnosis conversion in young patients with mood disorders. We performed a two-year follow-up study on 79 adolescent patients diagnosed with MDD or BD, with a detailed clinical assessment at five visits. We monitored diagnosis change from MDD to BD. The control group consisted of 31 healthy youths. According to the neurodevelopmental and neuroimmunological hypotheses of mood disorders, we analyzed serum levels of brain-derived neurotrophic factor (BDNF), proBDNF, epidermal growth factor (EGF), migration inhibitory factor (MIF), stem cell factor (SCF), and correlations with clinical factors. We detected a significant disease-dependent increase in EGF level in MDD and BP patients at baseline exacerbation of depressive or hypomanic/manic episodes as well as in euthymic state compared to healthy controls. No potential biological predictors of disease conversion were found. Replication studies on a larger cohort of patients are needed.

Download Full-text

A Randomized Controlled Trial on the Effectiveness of Epidermal Growth Factor-Containing Ointment on the Treatment of Solar Lentigines as Adjuvant Therapy

Medicina ◽

10.3390/medicina57020166 ◽

2021 ◽

Vol 57 (2) ◽

pp. 166

Author(s):

Hye One Kim ◽

Hye Ran Kim ◽

Jin Cheol Kim ◽

Seok Young Kang ◽

Min Je Jung ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Nd:Yag Laser ◽

Controlled Trial ◽

Control Group ◽

Therapeutic Effects ◽

Study Group ◽

Patient’S Satisfaction ◽

Epidermal Growth ◽

532 Nm

Background and Objective: Little is known about the anti-pigmentation effects of whitening agents on solar lentigines. Epidermal growth factor (EGF) has been used as a booster for wound healing in the skin, and it has been suggested to have anti-pigmentation effects. This study aimed to evaluate the effect and safety of EGF-containing ointment for treating solar lentigines with a Q-switched (QS) 532 nm neodymium-doped yttrium aluminum garnet (Nd:YAG) laser (Bluecore company, Seoul, Republic of Korea). Materials and Methods: Subjects who underwent QS 532 nm Nd:YAG laser treatment of solar lentigines were randomly assigned to treatment with an EGF ointment or petrolatum. After the laser procedure, the subjects were administered the test ointment twice a day for 4 weeks. The physician’s assessment of the degree of pigment clearance and patient’s satisfaction were assessed after 4 and 8 weeks. Additionally, the melanin index (MI), erythema index (EI), transepidermal water loss (TEWL), and post-inflammatory hyperpigmentation (PIH) were evaluated. This trial was registered with ClinicalTrials.gov (NCT04704245). Results: The blinded physician’s assessment using 5-grade percentage improvement scale and patient’s satisfaction were significantly higher in the study group than in the control group at the 4th and 8th weeks. The MI was significantly higher in the control group than in the study group at the 4th and 8th weeks. The EI and TEWL did not differ significantly between the two groups at either time point. The incidence of PIH was higher in the control group (37.5%) than in the EGF group (7.14%) at the 8th week. Conclusions: The application of EGF-containing ointment on facial solar lentigines with a QS 532 nm Nd:YAG laser showed efficient and safe therapeutic effects, with less PIH. Thus, EGF-containing ointment could be suggested as the promising adjuvant treatment strategy with a QS laser for solar lentigines.

Download Full-text

Serum levels of growth factors in patients with urinary bladder cancer

Turkish Journal of Biochemistry ◽

10.1515/tjb-2016-0129 ◽

2017 ◽

Vol 42 (5) ◽

Author(s):

Şölen Himmetoğlu ◽

Mustafa Bilal Tuna ◽

Eylem Efe Koç ◽

Süleyman Ataus ◽

Yildiz Dincer

Keyword(s):

Bladder Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Serum Level ◽

Urinary Bladder ◽

Urinary Bladder Cancer ◽

Serum Levels ◽

Control Group ◽

Her 2 ◽

Epidermal Growth

AbstractBackground:Altered signalling of human epidermal growth factor receptor-2 (HER-2/neu), insulin-like growth factor 1 (IGF-1) and epidermal growth factor (EGF) have been shown to play important role in tumor development and progression in various cancers. Their serum levels may be reliable indicator for diagnosis and progression of cancer.Objective:To examine the serum levels of soluble HER-2/neu (sHER-2/neu), IGF1 and EGF in patients with urinary bladder cancer (UBC).Material and methods:Serum levels of sHER-2/neu, IGF1 and EGF were measured by enzyme-linked immune assay in newly diagnosed, untreated patients with UBC.Results:In the patient group, sHER-2/neu level was found to be increased, IGF1 level was found to be decreased in comparison to those in the control group. Although serum level of sHER-2/neu was lower in the patients with Ta stage than that in the patients with T1 and T2 stages, this difference was not at a statistically significant level.Conclusion:Serum level of sHER-2/neu is increased in patients with UBC. Despite the lack of a significant association between sHER-2/neu level and pathological pT stage, sHER-2/neu may be a promising marker for UBC but IGF-1 and EGF have not such a potential.

Download Full-text

High epidermal growth factor concentration associated with somatic cell count in milk of cows with subclinical mastitis

Medycyna Weterynaryjna ◽

10.21521/mw.6396 ◽

2020 ◽

Vol 76 (06) ◽

pp. 6396-2020 ◽

Cited By ~ 1

Author(s):

AYRIS GOKCEOGLU ◽

GUL FATMA YARIM ◽

NILGUN GULTIKEN ◽

MURAT YARIM

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Somatic Cell ◽

Cell Count ◽

Somatic Cell Count ◽

Subclinical Mastitis ◽

Enzyme Linked Immunosorbent Assay ◽

Control Group ◽

Study Group ◽

Epidermal Growth

The aim this study was to determine the milk epidermal growth factor (EGF) concentration in cows with subclinical mastitis and its relationship with the somatic cell count (SCC). The animal material of this study was composed of 40 lactating cows aged 3-6 years. Subclinical mastitis was diagnosed using the California Mastitis Test and SCC in milk. The study group consisted of 20 cows with SCC > 200.000 cells/ml, and the control group comprised 20 cows with SCC < 200.000 cells/ml. EGF concentration in milk was determined using a bovine-specific enzyme-linked immunosorbent assay (ELISA) kit. The mean EGF concentration was 6.08 ± 2.91 ng/ml in the study group and 2.85 ± 1.87 ng/ml in the control group (P < 0.001). The results also indicated a significant correlation between SCC and EGF concentration in the study group (r = 0.965, P < 0.01). The findings of this study suggest that a milk EGF assay together with SCC could be useful for diagnosing mastitis as well as for monitoring udder health.

Download Full-text